In people, the most consistent signals are modest and mostly about biomarkers. For type 2 diabetes, the best-quality evidence does not show a clear, reliable benefit for HbA1c, fasting glucose, or insulin resistance over short follow-up, although some meta-analyses and individual trials report improvements in fasting glucose, insulin, or other markers. Lipid findings are mixed as well: one meta-analysis found lower total cholesterol, triglycerides, and LDL-C, while an earlier meta-analysis found no significant lipid changes. Inflammation results are also inconsistent, with some studies showing biomarker improvements and others finding inconclusive overall effects.56789101129